The importance of pediatric inflammatory bowel disease (IBD) has grown significantly, for the incidence of pediatric inflammatory bowel disease in Korea has been rapidly increasing in recent years. One quarter of the new IBD patients has been known to be presented in childhood. Growth and pubertal delay are one of key factors in the management of pediatric IBD. The focus of treatment in children should be to reduce or eliminate symptoms, optimize nutritional status and growth, and prevent complications. This review will deal with the evidence supporting the treatments currently used in children with inflammatory bowel disease.